Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1 için istatistikler

Toplam ziyaret

views
Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1 0

Aylık toplam ziyaret

views
Temmuz 2024 0
Ağustos 2024 0
Eylül 2024 0
Ekim 2024 0
Kasım 2024 0
Aralık 2024 0
Ocak 2025 0